s 20928 has been researched along with ml 23 in 1 studies
| Studies (s 20928) | Trials (s 20928) | Recent Studies (post-2010) (s 20928) | Studies (ml 23) | Trials (ml 23) | Recent Studies (post-2010) (ml 23) |
|---|---|---|---|---|---|
| 17 | 0 | 0 | 13 | 1 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robertson, AD; Willis, GL | 1 |
1 other study(ies) available for s 20928 and ml 23
| Article | Year |
|---|---|
Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Topics: 5-Methoxytryptamine; Animals; Male; Melatonin; Naphthalenes; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Melatonin; Recovery of Function | 2004 |